LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

Search

Cytokinetics Inc

Closed

SectorHealthcare

30.98 3.92

Overview

Share price change

24h

Current

Min

29.49

Max

31.51

Key metrics

By Trading Economics

Income

-11M

-161M

Sales

-15M

1.6M

EPS

-1.36

Profit margin

-10,220.139

Employees

498

EBITDA

13M

-125M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+154.8% upside

Dividends

By Dow Jones

Next Earnings

7 Aug 2025

Market Stats

By TradingEconomics

Market Cap

-1.1B

3.8B

Previous open

27.06

Previous close

30.98

News Sentiment

By Acuity

28%

72%

69 / 382 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Cytokinetics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

5 Jun 2024, 15:26 UTC

Acquisitions, Mergers, Takeovers

Cytokinetics CEO Says Board Would Have Backed Actionable Buyout

11 Apr 2025, 09:30 UTC

Top News

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs -- Heard on the Street -- WSJ

5 Jun 2024, 14:14 UTC

Acquisitions, Mergers, Takeovers

Cytokinetics: Board, Management Would Never Stand in Way of Value-Maximizing Transaction >CYTK

5 Jun 2024, 14:14 UTC

Acquisitions, Mergers, Takeovers

Cytokinetics CEO: Board Would Have Supported Actionable Proposal in Best Interests of Shareholders >CYTK

5 Jun 2024, 14:14 UTC

Acquisitions, Mergers, Takeovers

WSJ Reported in January That Novartis Backed Away From Pursuit of Cytokinetics >CYTK

5 Jun 2024, 14:14 UTC

Acquisitions, Mergers, Takeovers

Cytokinetics CEO: Other Party Didn't Move Forward With Acquisition >CYTK

5 Jun 2024, 14:14 UTC

Acquisitions, Mergers, Takeovers

Cytokinetics CEO: Board Was Supportive of Moving Forward on Deal on Terms Company Believed Would Be Mutually Acceptable >CYTK

5 Jun 2024, 14:14 UTC

Acquisitions, Mergers, Takeovers

Cytokinetics CEO: Previously Held Good-Faith Talks With Another Party on Acquisition of Company >CYTK

Peer Comparison

Price change

Cytokinetics Inc Forecast

Price Target

By TipRanks

154.8% upside

12 Months Forecast

Average 76.44 USD  154.8%

High 120 USD

Low 41 USD

Based on 20 Wall Street analysts offering 12 month price targets forCytokinetics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

20 ratings

18

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

32.3 / 40.43Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

69 / 382 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Cytokinetics Inc

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. It develops small molecule drug candidates primarily engineered to impact muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. The company has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.